Keywords: nine-month, sales, up, novo, nordisk, danish, company
Nine-Month Sales Up 15% At Novo Nordisk
Article | 14 November 1997
Danish company Novo Nordisk has reported a consolidated sales increaseof 15% for the first nine months of 1997 to 12.35 billion Danish kroner ($1.9 ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
